Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,502 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison Arm Clear all

Conditions: Prostate Cancer
Interventions: ciprofloxacin, placebo, quality-of-life assessment, laboratory biomarker analysis; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Any Condition With a Clinical Indication for PET/CT Exam
Interventions: PET/MRI system; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: San Francisco, California • Stanford, California

Conditions: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, HIDA; Drug · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, Access and Linkage to Healthcare, Technology Use
Interventions: PEPPI Pharmacies; Other
Lead sponsor: EMPOWERX INC; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Peripheral Nerve Injuries
Interventions: NeuroSpan Bridge, NeuroGen Nerve Guide, Nerve Autograft; Device
Lead sponsor: Auxilium Biotechnologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 5 more

Conditions: Spinal Cord Injuries, Neuropathic Pain
Interventions: Cognitive Multisensory Therapy, Usual Care, Clinical Assessment, Magnetic Resonance Imaging (MRI), OPTIONAL: blood draw; Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relapsed or Refractory Follicular Lymphoma
Interventions: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more

Conditions: Coronary Artery Disease
Interventions: Motivational Interviewing (MINT), Mailed DVD; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Tropifexor (LJN452), Cenicriviroc (CVC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 21 more

Conditions: Cognitive Behavioral Therapy, Sleep Initiation and Maintenance Disorders, Sleep Deprivation, Sleep Disorders, Intrinsic
Interventions: firefighter Sleep Health Coaching Intervention (ffSHC), Control (Minimally Enhanced Usual Care); Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OROS methylphenidate, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: MSB11022, Humira®; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more

Conditions: Hypogonadal Males
Interventions: Testosterone Gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Hepatitis C
Interventions: ABT-072; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: HIV/AIDS
Interventions: Individual Telephone Counseling Intervention, Group Arm, Book Arm; Behavioral · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opiate Addiction
Interventions: CBD 400 mg, CBD 800 mg, Control (placebo); Drug
Lead sponsor: Hurd,Yasmin, Ph.D.; Individual
Eligibility: 21 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Ischemic Stroke, Obstructive Sleep Apnea
Interventions: PAP, HLE; Device · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Water Intake
Interventions: Air Up® Peach Pod, Air Up® Orangeade Pod; Dietary Supplement
Lead sponsor: air up GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Lumbar Spine Injury, Spinal Fusion, Frailty, Prehabilitation, Nutritional Supplementation, Functional Outcome
Interventions: Multimodal Prehabilitation, Standard Pre-Surgical Clinical Care; Other
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions: PF-06821497, Docetaxel, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 49 more

Conditions: Systemic Sclerosis
Interventions: BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 16 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 17
States / cities: Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: Cervical Cancer, Behavior
Interventions: Care Group Cervical Cancer Screening Education Curriculum; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 30 Years to 59 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine
Interventions: Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

Comparison of 18F FDG PET/CT TO PET MRI

Pilot Study for Patients With Poor Response to Deferasirox

PEP/PrEP Via Pharmacist-Prescribing Implementation (PEPPI)

A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair

Identifying Body Awareness-related Brain Network Changes During Cognitive Multisensory Rehabilitation for Reduced Neuropathic Pain in People With Spinal Cord Injury

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Evaluating Worksite Sleep Health Coaching in Firefighters: The Sleep Assistance for Firefighters Study

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Self-Managing HIV and Chronic Disease

Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

The Recovery in Stroke Using PAP Study

A Three-Group Study to Examine the Efficacy of the Air up® Drinking System at Improving Hydration and Associated Health Outcomes

Does Prehabilitation Improve Outcomes in Patients Undergoing Complex Spine Fusion Surgery?

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Reducing Barriers and Sustaining Utilization of a Cervical Cancer Screening Program in Rural Senegal

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers